ITHACA, N.Y.–(BUSINESS WIRE)–AvantGuard, Inc., a biotechnology company developing next-generation antimicrobial technologies inspired by the human immune system, today announced a peer-reviewed study demonstrating that its AVA-003 compound significantly outperformed chlorhexidine gluconate (CHG), the current standard-of-care agent for decolonizing skin of Candida auris (recently reclassified as Candidozyma auris), in a validated mouse model. Conducted independently at Case Western Reserve Uni

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.